RNA

Prosensa: Back Into The Limelight

moreView todays social media effects on RNAView the latest stocks trending across Twitter. Click to view dashboardSee who Prosensa is hiring next, click here to view […]

6:00 pm Prosensa Holding announces 48-week data from U.S. Phase 2 study of drisapersen in 51 DMD boys: Clinically meaningful improvement from 24-week treatment period was maintained for 24 weeks after drisapersen administration ceased

moreView todays social media effects on RNAView the latest stocks trending across Twitter. Click to view dashboardSee who Prosensa is hiring next, click here to view […]

Prosensa Announces 48-Week Data from a U.S. Phase II Placebo-Controlled Study of Drisapersen in 51 DMD Boys

[GlobeNewswire] – Chicago, IL — Prosensa Holding N.V. (NASDAQ: RNA), the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, today reported encouraging 48-week … moreView todays social media effects on RNAView the latest stocks trending across Twitter. Click to view dashboardSee who Prosensa is hiring next, click here to view […]

4 Biotech Stocks Under $10 Moving Higher

moreView todays social media effects on RNAView the latest stocks trending across Twitter. Click to view dashboardSee who Prosensa is hiring next, click here to view […]